European Journal of Surgical Oncology
Volume 34, Issue 12 , Pages 1299-1303 , December 2008

Prognostic relevance of proliferative activity evaluated by Mib-1 immunostaining in node negative breast cancer

,Accepted 15 November 2007.

References 

  1. Goldhirsh A, Glick JH, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005;16:1569–1583
  2. Mirza AN, Mirza NQ, Vlastos G, Singletary E. Prognostic factors in node-negative breast cancer. Ann Surg. 2002;235:10–26
  3. Colozza M, Azambuja E, Cardoso F, Sotiriu C, Larsimont D, Piccart MJ. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?. Ann Oncol. 2005;16:1723–1739
  4. Liu S, Edgerton SM, Moore DH, Thor AD. Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin Cancer Res. 2001;7:1716–1723
  5. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005;23:7212–7220
  6. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–322
  7. Clarke RB, Howell A, Potten CS, Anderson E. Dissociation between steroid receptor expression and cell proliferation in human breast. Cancer Res. 1997;57:4987–4991
  8. Cattoretti G, Becker MH, Key G, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (Mib1 and Mib3 detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol. 1992;168:357–363
  9. Marrelli D, Pinto E, Neri A, et al. Mib-1 proliferation index is an independent predictor of lymph node metastasis in invasive breast cancer. A prospective study on 675 patients. Oncol Rep. 2006;15:425–429
  10. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710–1715
  11. Offersen BV, Sorensen FB, Knoop A, Overgard J. The prognostic relevance of proliferative activity in early breast cancer. Histopathology. 2003;43:573–582
  12. Gaglia P, Bernardi A, Venesio T, et al. Cell proliferation of breast cancer evaluated by antiBrdU and anti Ki-67 antibodies: its prognostic value on short term recurrences. Eur J Cancer. 1993;29A:1509–1513
  13. Weikel W, Brumm C, Wilkens C, Beck T, Knapstein PG. Growth fractions (Ki-67) in primary breast cancers, with particular reference to node negative tumors. Cancer Detect Prev. 1995;19:446–450
  14. Seshadri R, Leong AS, McCaul K, Firgaira FA, Setlur V, Horsfall DJ. Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis. Int J Cancer. 1996;69:135–141
  15. Broen RW, Allred CD, Clark GM, Osborne CK, Hilsenbek SG. Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res. 1996;2:585–592
  16. Haerslev T, Jacobsen GK, Zedeler K. Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in breast cancer. Breast Cancer Res Treat. 1996;37:101–113
  17. Molino A, Micciolo R, Turazza M, et al. Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis. Int J Cancer. 1997;74:433–437
  18. Iacopetta B, Grieu F, Powell B, Soong R, McCaul K, Sashadri R. Analysis of p53 gene mutation by polymerase chain reaction – single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer. Clin Cancer Res. 1998;4:1597–1602
  19. Thor AD, Liu S, Moore DH, Edgerton SM. Comparison of mitotic index, in vitro bromodeoxyuridine labelling and Mib-1 assays to quantitate proliferation in breast cancer. J Clin Oncol. 1999;17:470–477
  20. Clahsen PC, van de Velde CJ, Duval C, et al. The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer. Eur J Surg Oncol. 1999;25:356–363
  21. Billgren AM, Tani E, Liedberg A, Skoog L, Rutqvist LE. Prognostic significance of tumor cell proliferation analyzed in fine needle aspirates from primary breast cancer. Breast Cancer Res Treat. 2002;71:161–170
  22. Trihia H, Murray S, Price K, et al. Ki-67 expression in breast cancer. Its association with grading systems, clinical parameters and other prognostic factors – a surrogate marker?. Cancer. 2003;97:1321–1331
  23. Joensuu H, Isola J, Lundin M, et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res. 2003;9:923–9330
  24. Railo M, Luldin J, Haglund C, von Smitten K, Nordling S. Ki-67, ER receptors, ploidy and S phase as long-term prognostic factors in T1 node-negative breast cancer. Tumour Biol. 2007;28:45–51
  25. Spyratos F, Ferrero-Pous M, Tressard M, et al. Correlation between Mib-1 and other proliferation markers. Clinical implications of the Mib-1 cutoff value. Cancer. 2002;94:2151–2159
  26. Colleoni M, Rotzmens N, Peruzzotti G, et al. Minimal and small size invasive breast cancer with no axillary involvement: the need for tailored adjuvant therapies. Ann Oncol. 2004;15:1633–1639
  27. Soerjomataram I, Louwman WJ, Ribot JG, Roukema JA, Coebergh WE. An overview of prognostic factors for long term survivors of breast cancer. Breast Cancer Res Treat. 2007;22:[ePub ahead of print]
  28. Hanrahan EO, Valero V, Gonzales-Angulo AM, Hortobagy GN. Prognosis and management of patients with node-negative invasive breast carcinoma that is 1cm or smaller in size (stage 1; pT1a,bN0Mx): a review of the literature. J Clin Oncol. 2006;24:2113–2122

PII: S0748-7983(07)00618-X

doi: 10.1016/j.ejso.2007.11.009

European Journal of Surgical Oncology
Volume 34, Issue 12 , Pages 1299-1303 , December 2008

Article Tools